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Abstract: Since the activity of several conventional anticancer drugs is restricted by resistance mechanisms and dose-limiting side-
effects, the design of formulations for local application on malignant lesions seems to be an efficient and promising drug delivery ap-
proach.  
In this study, the effect of locally applied 5-FU on cell death was evaluated both in a SCC4/HEK001 model and in a newly proposed 3D 
outgrowth model of oral squamous cell carcinoma (OSCC). Initially, the optimal drug dose was established by delivery of solutions con-
taining different amounts of 5-FU. The solution containing 1% (w/v) of 5-FU resulted effective in inducing cell death with complete 
eradication of cell colonies. 
Buccal tablets were designed to deliver 5-FU locoregionally to the cancer lesions of the oral cavity. Tablets were prepared using a drug 
loaded matrix of acrylic/methacrylic acid copolymer containing 1% (w/w) of 5-FU and applied on 3D outgrowths. The drug release from 
tablets appeared to be sufficient to induce cell death as confirmed by transmission electron microscopy and enzymatic assay (TUNEL). 
After 120 h of treatment, when about 90% of the drug had been discharged from the tablets into the culture environment, 5-FU caused 
loss of cell-cell communications and apoptotic cell death. After 192 h, a complete disaggregation of the 3D oral outgrowths and the death 
of all the cells was observed. 
Buccal matrix tablets could be considered a promising new approach to the locoregional treatment of OSCC. Risks of systemic toxicity 
are avoided since very low drug doses are delivered. 
Keywords: 5-Fluorouracil, Locoregional drug delivery, Oral squamous cell carcinoma, Buccal tablets, Tissue engineering, 3D oral out-
growths. 
1. INTRODUCTION 
 Although tumors of a variety of histologic types may arise 
within the oral cavity, more than 90% of these tumors are squamous 
cell carcinomas [1]. The risk factors most commonly associated 
with the progress of oral squamous cell carcinoma (OSCC) include 
cigarette smoking, exposure to second-hand smoke, the consump-
tion of betel nuts, heavy alcohol consumption, infection with vi-
ruses and advanced age [2,3]. Tobacco and alcohol usage are the 
most important avoidable risks, although only a small fraction of 
people who are exposed to these agents develop OSCC. This cancer 
kills men at a much higher rate than women, and the mortality rate 
is highest among black men. 
 These considerations provide further confirmation to the con-
cept of wide differences in genetic susceptibility to carcinogen ex-
posure [4-6]. OSCC of the buccal mucosa can be especially aggres-
sive. Cancer of the buccal mucosa arises more frequently from pre-
existing leukoplakia than cancers of the oral cavity.  
 Molecular alterations causing oral carcinogenesis have been 
linked to genetic factors involving chromosomal aberrations, tumor 
suppressor genes, oncogenes, DNA mismatch repair genes, envi-
ronmental and viral factors. It is likely that sequential and/or con 
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comitant mutations or defects enable the transformed epithelial 
cells to proceed through precancerous progression and malignant 
conversion with a metastatic potential. In a few words, squamous 
cell carcinoma is characterized as exophytic or ulcerative lesions or 
a combination of both. Exophytic lesions are generally less com-
mon than ulcerative lesions; they grow slowly and are little infiltra-
tive. In advanced cases, the exophytic lesions can become deeply 
infiltrative and invasive. On the other hand, ulcerative lesions are 
common and often appear as red or grey ulcers with heaped 
boundaries that bleed easily. These ulcerative lesions can be deeply 
infiltrative [7].  
 During the past decades, there has been an extensive evolution 
in the knowledge on oral cancer. Despite these developments, the 5-
year overall patient survival has experienced little progression, 
while the quality of life of patients has notably improved [8].  
 Treatment of oral cancer has primarily relied on classical mo-
dalities encompassing surgery, radiation, and chemotherapy or a 
combination of these methods [9].  
 The surgical removal of the tumor may result in facial distortion 
and can adversely affect the patient’s ability to speak and swallow. 
In addition, oral cancer surgery can lead to complications such as 
injury to neurovascular structures, reduced mouth opening associ-
ated with patient’s perception of chewing deficit, wound infection, 
or salivary fistula. Post-operative sialoceles and fistulas may inter-
fere with wound healing.  
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 The most frequently observed complications resulting from 
radiation therapy include tooth decay and dental caries, tissue 
edema and erythema, decreased salivation or xerostomia, osteoradi-
onecrosis of the mandible, periodontal disease and dysphagia [10]. 
The successful treatment of OSCC depends on the appropriate 
treatment of the primary site. Increased tumor size (T stage), the 
presence and number of nodal metastases (N stage), the spread of 
tumor outside of the lymph node capsule, and perineural invasion 
by the primary tumor are the most consistent adverse outcomes of 
delayed treatment. Cancer of the buccal mucosa has multiple poten-
tial routes of spread to the adjacent areas in the head and neck [11]. 
 Despite the fact that some patients may be successfully treated 
with surgery and/or radiotherapy, the majority are treated with 
chemotherapy, in order to ameliorate the quality of life, convert 
inoperable tumors into operable as well as to improve the locore-
gional tumor control and long-term survival rate [12]. 
 In addition to debulking surgery, the main treatment modality in 
cancer therapy is chemotherapy, nevertheless its role in treatment of 
patients with oral cancer is not well established yet. 
 Systemic chemotherapy regimens appear to be efficient locally 
and in the subsumed prevention of metastatic spread, but they are 
also associated with severe toxicity and morbidity, potentially rele-
vant to the survival rate. Many chemotherapeutic agents can simul-
taneously improve the survival rate of patients with cancer and 
result in adverse effects, owing to the lack of specificity. Anticancer 
drugs have toxic effects on normal tissues and have a very narrow 
therapeutic window. Recently, it has been reported that nerve cell 
function can also be disrupted and neurotoxicities (i.e. peripheral 
neuropathy, cognitive changes and humour alterations) could be 
developed [13]. Chemotherapy is beneficial for local control and 
survival improvement, although it does not always induce a sub-
stantially positive response. Many tumors present a satisfactory 
response when they are first exposed to chemotherapeutic agents. 
However, drug resistance occurs sooner or later in these tumors, 
and the majority of the patients develop progressive disease [14]. 
The lack of effective chemotherapy results in a high death rate in 
patients with OSCC. In particular, high doses of chemotherapeutic 
agents could cause the development of resistant cell lines that rep-
resent a major obstacle in cancer therapy [15].  
 5-Fluorouracil (5-FU) is currently used in systemic treatment of 
oral, gastrointestinal, breast, pancreas and skin neoplasms, either 
alone or associated with other drugs [9,12,15-17]. It is still one of 
the most widely used anticancer agents developed over the past 10 
years, for chemotherapy regimens aimed at enhancing local tumor 
control, reducing distant metastases and preserving anatomical 
functions.  
 5-FU is an antimetabolite that induces apoptotic death of the 
cancer cells [16]. In vitro studies demonstrated that 5-FU, also in 
oral cancer, causes apoptosis that could be caspase-dependent and 
might vary in different tumor cell lines [9,12,15,16,18]. Neverthe-
less, to induce apoptosis, high 5-FU concentrations next to cancer 
cells are needed. 
 Since 5-FU is poorly absorbed from gastrointestinal tract, it is 
usually administered by slow intravenous continuous infusion or 
bolus. It has been demonstrated that protracted venous infusion is 
more effective, in terms of percentage of effectiveness, than intra-
venous bolus, although the biological mechanism responsible for 
this phenomenon is unclear [19].  
 After intravenous administration its plasmatic half-life is about 
16 min and it is dose-dependent. Severe and unpredictable adverse 
reactions to 5-FU are mainly attributed to deficiency of dihydro-
pyrimidine dehydrogenase (DPD), an enzyme encoded by the 
DPYD gene. This enzyme is the rate-limiting step in catabolism of 
5-FU and deactivates more than 80% of its standard dose. The defi-
ciency of DPD, resulting in poor enzymatic activity, increases the 
half-life of 5-FU and causes drug accumulation and severe toxicity 
[20]. The major toxic effects of 5-FU regimens result in myelosup-
pressive action and gastrointestinal toxic effect. Loss of the integ-
rity of the gastrointestinal mucosal barrier associated with neutro-
penia is the most common cause for the risk of fatal toxicity associ-
ated with bolus 5-FU. Moreover, non-specific distribution of drug 
in tumors, as well as in normal tissues, can result in an undue toxic-
ity [19].  
 The clinical use of 5-FU is strongly limited by the acquired or 
inherent resistance, which is thought to mediate therapeutic efficacy 
in cancer chemotherapy. To overcome 5-FU resistance in OSCC, a 
combination of anticancer agents is usually used to reduce these 
resistance determinants via alternative applications [21]. However, 
the inconveniences associated to the toxicity often prevent the use 
of the adequate dose and sufficient period for the desired results. 
These effects could be lowered by topical applications. Five percent 
5-FU cream is approved by the FDA for the treatment of superficial 
basal cell carcinomas (BCC) but has so far been underutilized. The 
mechanism of action of topical 5-FU in treating superficial 
malignancies is thought to be similar to that of intravenous 5-FU 
[22-24].  
 It has been reported that low concentration formulations pro-
vide efficacy on skin diseases equal to that of currently available 
formulations containing high amounts of 5-FU [25].  
 Strategies able to increase the anticancer activity and to cir-
cumvent resistance are either discovery of new drugs or improving 
delivery of conventional chemotherapeutics. Established anticancer 
drugs have the advantage of well known pharmacological and toxi-
cological proles.  
 Our working hypothesis is that locoregional 5-FU delivery can 
reduce the risk of systemic toxicity while preserving the efficacy 
also in treatment of OSCC. To date, the most common local treat-
ment is limited to chemoprevention. However, applications of a 2-3 
min topical drug solution-painting onto premalignant lesions of oral 
mucosa has a controversial effectiveness. Usually, the oral saliva 
and mechanical activities will remove the medication painted on 
mucosal surface quickly. It is difficult to use such painting treat-
ment to retain an agent solution on targeted tissue surface with ade-
quate concentration and sufficient retention time [26]. Solid dosage 
forms applied on cancer lesions of buccal mucosa could be able to 
prolong the medication retention time on the targeted tissue, allow-
ing high drug concentration in a local area, decreasing the risks of 
toxic and dose-dependent side-effects of systemic drug delivery, 
while they do not require expertise for administration.  
 Tissue-engineered oral mucosal equivalents have been devel-
oped for in vitro studies of biocompatibility, for mucosal irritation 
and for oral disease to better understand disease process and dis-
cover new treatments [27,28]. In the present work we have used a 
novel 3D in vitro model that enabled us to perform mid- to long-
term cultures of both normal and malignant oral mucosa [29]. Using 
this model could lead to an increased understanding of the features 
of OSCC progression and to the discovery of new potential thera-
peutic strategies. 
 Following the development of a suitable formulation to be ap-
plied on culture of primary oral squamous cell carcinoma in a 3D 
model, in this study the effects on cell survival of topically applied 
1% 5-FU tablets was evaluated as a potential therapeutic means 
against OSCC. 
2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Chemicals 
 5-Fluorouracil (5-FU), USP grade, 3-[4,5-dimethylthiazol-2-
yl]-2,3-diphenyl tetrazolium bromide (MTT) and Proteinase K were 
purchased from Sigma-Aldrich (Milan, Italy). Acrylic and 
methacrylic acid copolymer (described in USP/NF as ammonio 
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methacrylate copolymer “type B”) was kindly supplied by Rofarma 
(Milan, Italy). HCl was purchased from Titolchimica (Pontecchio, 
Italy) and isopropanol from Carlo Erba (Milan, Italy). Glutaralde-
hyde, osmium tetroxide (OsO4), epoxy resin (Epon812) and epoxy 
accelerator (DMP30) were purchased from Electron Microscopy 
Sciences (Hatfield, PA, USA). 1,2-Propylene oxide was purchased 
from Merck (Darmstadt, Germany). 3,3'-Diaminobenzidine 
(DAB) was purchased from Millipore (Billerica, MA, USA). 
Buffer solution (pH 6.8) simulating saliva was prepared by dissolv-
ing NaCl (0.126 g), KCl (0.964 g), KSCN (0.189 g), KH2PO4 
(0.655 g), Na2SO4 10H2O (0.763 g), NH4Cl (0.178 g), CaCl2 
2H2O (0.228 g), NaHCO3 (0.631 g), and urea (0.200 g) in 1 L of 





solution (pH 7.4) was prepared by dissolving KH2PO4 (0.144 g), 
anhydrous Na2HPO4 (0.795 g) and NaCl (9.0 g) in 1 L of distilled 
water.  
 All chemicals and solvents were of analytical grade and were 
used without further purification. 
2.1.2. Cell Culture Reagents 
 Recombinant human EGF (hEGF) was purchased from Cell 
Signaling Technology (Beverly, MA, USA). L-Glutamine was ob-
tained from Stem Cell Technologies (Tukwila, WA, USA). Hydro-
cortisone (H400) and Dulbecco's Modified Eagle's Medium 
(DMEM) were purchased from Sigma-Aldrich (Milan, Italy). 
GIBCO™ Keratinocyte-Serum Free Medium (Keratinocyte-SFM) 
and Ham's F12 medium were obtained from Invitrogen Life Tech-
nologies (Carlsbad, CA, USA). Fetal bovine Serum (FBS), Hanks 
BSS without phenol red (HBSS) and Phosphate Buffered Solution 
(PBS) were purchased from Lonza, (Cologne, Germany). 
Veloderm
®
 (kindly supplied by the Bioskin Trade Com-
pany,Ancona, Italy) is a freely permeable, 0.1 mm thick membrane, 
commonly used as wound dressing. It is a natural micro-porous 
polymeric dressing, made from cellulose microfibrils called Crys-
talcell 77™; its fibers, as evidenced by scanning electron micros-
copy analysis, show regular structure with inter-fibrillar spaces 
large enough to allow transfer of large molecules from one to the 
other side of the membrane [30]. 
2.2. Methods 
2.2.1. Cell Cultures 
2.2.1.1. Cell Lines 
 Human squamous cell carcinoma cell line (SCC4, from LGC 
Standards, Milan, Italy) was grown in a 1: 1 mixture of DMEM and 
Ham's F12 medium supplemented with 2 mM L-glutamine, 400 
ng/ml hydrocortisone and 10% FBS. These cells originated from a 
squamous cell carcinoma of the tongue of a 55 years old male pa-
tient. Human skin keratinocyte cell line (HEK001, from LGC Stan-
dards) was grown as a monolayer in Keratinocyte-SFM, supple-
mented with 5 ng/ml h-EGF and 2mM L-glutamine. These cells are 
derived from normal skin keratinocytes immortalized by human 
papillomavirus 16 (HPV-16) E6/E7, and were used as a control for 
the SCC4. Medium was changed every 2 days and both cell lines 
were cultured at 37°C, 5% CO2 atmosphere in 25 cm
2 
flasks (Corn-
ing Life Sciences, Amsterdam, The Netherlands). Subcultures be-
fore confluency were performed harvesting adherent cells by tryp-
sin digestion in HBSS, washing with PBS and resuspending cells in 
fresh growth medium. 
2.2.1.2. Three-dimensional Cancerous Oral Outgrowth Model 
 OSCC samples were obtained from patients referred to the Unit 
of Oral Medicine of the University of Palermo, Italy. The following 
adopted procedures, conforming to the relevant ethical guidelines 
for human research, were in agreement with the Helsinki Declara-
tion of 1975, as revised in 1983, and approved by the Ethic Council 
of the Policlinico-Hospital of the University of Palermo. Each pa-
tient suffering from neoplastic oral lesion was subjected to topical 
antifungal therapy (miconazole 2% oral gel, Daktarin, Janssen-
Cilag) 3 times daily before the biopsy, after written informed con-
sent. After 1 min of treatment with commercial 0.2% chlorhexidine 
oral rinse (Broxo Din, Laboratorio Farmaceutico S.I.T), OSCC 
samples were obtained by using 6 mm diameter punch biopsy on 
the lesion margin with clinically healthy tissue. Each sample was 
divided into two parts. The outer part of the sample was fixed in 
formalin and sent for histo-cytopathological examination, while the 
inner part was immediately placed in fresh culture medium and 
processed for the 3D oral outgrowths.  
 The method employed to obtain 3D human oral outgrowths 
from normal human oral mucosa has already been described [29]. 
The 3D OSCC outgrowths were obtained similarly. Briefly, the 
biopsies were cut using a sterile scalpel into 0.5 mm
3
 pieces and 
placed onto 6.5 mm Transwells (Becton Dickinson, Franklin Lakes, 
NJ, USA) embedded in 60 l of Matrigel (Becton Dickinson). The 
Transwells were put on 24 wells culture plates (Corning Life Sci-
ences) and 330 l of growth medium mix was added to each well. 
This mix was constituted of Keratinocyte-SFM supplemented with 
5 ng/ml of h-EGF and DMEM supplemented with 10% FBS (1: 1) 
which was placed underneath the nylon membrane of the Tran-
swells. The outgrowths were cultured at 37°C in a 5% CO2 atmos-
phere and the medium was changed every 48 h. An inverted light 
microscope equipped with phase contrast rings (LEICA DM-IRB, 
Leica Microsystems Srl, Milan, Italy) was used to monitor the out-
growths. 
2.2.3. Cell Treatment  
2.2.3.1. Cell Treatment with 5-FU Solutions  
 Cell lines, SCC4 and HEK001, were seeded at 1x10
4
 cells/ml in 
24-well plates. After cells reached approximately 80% of conflu-
ence, they were rendered quiescent with 1% FBS medium for 24 h. 
5-FU treatment of the outgrowths was performed when these had 
reached complete 3D differentiation (10-14 days). A stock solu-
tion was prepared by dissolving 5-FU in PBS, while the working 
solutions were obtained by diluting it in the growth medium. To 
identify in the cell lines the optimal 5-FU dilutions necessary 
to induce adequate levels of cell death (MTT test) 1 ml of 0.05, 
0.1, 0.5, 1 and 5% (w/v) solutions respectively were added to the 
outgrowths in the culture wells. Treatment of the outgrowths 
was carried out for up to 10 days with 330 μl of the same solu-
tions that were placed underneath the Transwell membrane; 
induction of cell death was evaluated morphologically. Un-
treated outgrowths were considered as control.  
2.2.3.2. Cell Treatment with 5-FU Loaded Tablets  
 In order to evaluate the mid- to long-term effects of topical 5-
FU treatment on cell survival, 3D OSCC outgrowths were treated 
with tablets containing 1% (w/w) of 5-FU (see section 2.2.7). Out-
growths were grown until complete 3D differentiation (10-14 days), 
and then aliquots (weighing 23 ± 1.0 mg) of tablets containing 5-
FU were added on top of the matrigel layer of the outgrowths. To 
avoid possible adverse mechanical effects of the tablets on the cells, 
a Veloderm®
 
membrane was positioned between the matrigel and 
the 5-FU loaded tablets. 200 μl of growth medium mix (Keratino-
cyte-SFM/DMEM 1: 1) was added on top of the tablets to facilitate 
drug delivery on the cell layers. Untreated controls, with drug un-
loaded matrix tablets positioned on top of the Veloderm® mem-
brane, were used to verify the potential adverse effects of the 
Veloderm® and tablet system on cell survival. The treatment was 
carried out for up to 8 days with 48, 120 and 192 h time points cho-
sen for the evaluation of the effects on cell survival. In experiments 
at 120 h and 48 h after the start of the experiment, the growth me-
dium was collected from the bottom plate and replaced with fresh 
medium; in experiments at 192 h replacement was accomplished at 
respectively 48 and 120 h after the start. For all time points, out-
growths were processed for electron microscopy and TUNEL 
analysis as described in sections 2.2.6 and 2.2.7.  
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2.2.4. Drug recovery in the Culture Medium after Cell Treatment 
with 5-FU Tablets 
 The withdrawals collected in experiments at 48, 120 and 192 h 
time points were analyzed to determine the amount of drug trans-
ferred onto the bottom plate. At the end of each experiment, the 5-
FU recovery was evaluated as the cumulative amount of drug re-
leased from tablets and transferred into the culture medium through 
the outgrowths. Drug assays were carried out as described in sec-
tion 2.2.9.2. As control, drug recovery assay was carried at the 
same time points in absence of 3D outgrowths to also evaluate drug 
release in the whole system.  
2.2.5. Cell Viability Test 
 The mitochondrial activity of SCC4 and HEK001 cell lines, 
after exposure to 5-FU, was evaluated using the MTT assay. After 5 
h and 24 h of incubation, the medium containing 5-FU was re-
moved, MTT was dissolved in fresh growth medium mix and 
added to the cell lines at a final concentration of 0.5 mg/ml. Follow-
ing a 2 h incubation period at 37°C, the converted dye was solubi-
lized with 1 ml acidic isopropanol (0.04 M HCl in absolute isopro-
panol) and optical density (OD) was measured at 570 nm, with 
background subtraction at 690 nm, using a spectrophotometer (Ul-
trospec 1000, Amersham Pharmacia Biotech, Uppsala, Sweden). 
Cell viability was expressed as the percentage of the OD value of 5-
FU-treated cells compared with untreated controls, according to the 
following equation: Viability = (OD sample/OD control) x 100. 
Each experiment was carried out in duplicate.  
2.2.6. Electron Microscopy  
 Immediately after excision of the nylon membrane from the 
Transwells using a scalpel, the 3D OSCC outgrowths were cut in 
pieces and fixed in a solution of 2.5% glutaraldehyde in PBS for 20 
minutes at room temperature. The pieces were post-fixed in 1% 
OsO4 for 2 h, dehydrated in an ascending graded series of ethanol, 
infiltrated with Epon812, in propylene oxide (1: 3, 1: 2, 1: 1 for 30 
min at room temperature respectively) and finally embedded in 
Epon812 with DMP30. The resin was then polymerized at 60°C for 
48 h. Ultrathin and semithin sections were cut with an ultramicro-
tome (Ultracut E, Reichert-Jung, Depew, NY, USA) at different 
thicknesses and mounted on copper grids and on glass slides for 
further use.  
2.2.7. In situ Apoptosis Detection 
 Semithin sections (about 2 m thick) were cut with an ultrami-
crotome, collected on poly-L-lysine coated slides (Thermo Fisher 
Scientific, Illkirch Cedex, France), and air-dried at room tempera-
ture. A controlled corrosion of the section surface was obtained by 
etching the sections for at least 8 min in a solution composed of 
saturated sodium hydroxide in absolute ethanol diluted to 50% with 
absolute ethanol. After rehydration in descending graded series of 
ethanol to water, sections were treated with Proteinase K for 15 
minutes at room temperature, and incubated with 3% hydrogen 
peroxide in PBS for 5 min. The ApopTag Peroxidase In Situ Apop-
tosis Detection kit (Millipore, Billerica, MS, USA) was used to 
label the free 3’-OH fragment DNA. Briefly, a working strength 
Terminal deoxynucleotidyl transferase solution was prepared ac-
cording to the kit protocol and applied to the section for 1 h at 
37°C. A stop/wash buffer solution was applied for 10 min at room 
temperature and slides were then treated with anti-digoxigenin-
peroxidase for 30 min at room temperature. Samples were then 
washed four times in distilled water and DAB, as peroxidase sub-
strate, was added for 10 min. Finally, the specimens were washed 
with distilled water and mounted under a coverslip in a permanent 
mounting media (Millipore). Three independent observers exam-
ined the specimens in a blind approach using a light microscope. 
Five optical fields for each section were selected and the total cell 
numbers and TUNEL-positive cell numbers were obtained from 
each. The percentage of TUNEL-positive cells is described as the 
percentage of TUNEL-positive cells relative to the total number of 
cells in each sample. All the observations were made at a magnifi-
cation of 400 x and the means of triplicate counts were used for 
statistical analyses. 
2.2.8. Preparation of 5-FU Loaded Matrix Tablets 
 Solid dispersion (matrix) containing 1% w/w of 5-FU was pre-
pared as previously reported [31]. Briefly, the accurately weighed 
amount of 5-FU was solubilized in acetone. To the obtained clear 
solution, the appropriate amount of acrylic and methacrylic acid 
copolymer was added in order to obtain the final matrix. After sol-
vent evaporation, the obtained solid mass was powdered and air-
dried at room temperature for 24 h. The amount of 5-FU entrapped in 
the matrix was determined spectrophotometrically. Tablets (13 
mm diameter, 1.33 cm2 surface and 1.20 mm thickness, weighing 
200 mg), were obtained by direct compression (10 tons) of drug 
loaded matrix using a hydraulic, single die, tabletting machine (IR 
Accessory PerkinElmer, Waltham, MS, USA), two flat-faced 
punches and a die. Before compression, the crushed matrix was 
passed through a standard mesh wire stainless steel sieve with an 
aperture size of 200 μm (Endecotts Ltd., London, UK).  
2.2.8.1. Drug Release from Tablets 
 The drug release from tablets, in buffer solution simulating 
saliva, was assessed using the flow through system previously de-
scribed [32]. Briefly, the system consists of a buffer solution simu-
lating saliva container (100 ml) from which liquid is forced to a 
release chamber. The flow rate of saliva is controlled by a peristal-
tic pump (Bio-Rad Econo Pump, Hercules, CA, USA) and main-
tained constant (1.2 ml/h) during the experiments. In the chamber, 
the salivary film wetting the tablet is about 0.1 mm thick. During 
the flow through, simulating saliva wets the drug loaded tablet en-
riching it in 5-FU content. The temperature is controlled by sub-
merging the chamber and the saliva container in a thermostatic bath 
(37 ± 0.1 C°). The drug amount in the saliva solution is then quanti-
tatively determined spectrophotometrically (see section 2.2.9.2). 
Experiments were performed on six tablets of six different batches 
and mean results were reported (n=6). The residual drug content in 
the tablets after release studies was determined. The amount of drug 
released and the residual drug content in the tablet matched the 
original drug content within 2-6%. Release data were elaborated 
using Curve Expert version 1.3 and Kaleidagraph as software, and 
fitted to the equations usually applied in release studies [33]. Linear 
or non-linear least squares fitting methods were used to determine 
the optimum values for the parameters present in each equation. 
Fittings were validated by using chi-square test. A P value less than 
0.05 was considered to be statistically significant. 
2.2.9. Drug Assay 
 UV spectrophotometric quantitative determinations were ac-
complished using an UV/VIS Shimadzu mod. 1700, Pharmaspec 
instrument (Shimadzu, Kyoto, Japan). The absorption peaks were 
highly reproducible and linearly related to concentration over a 
range 0.001-0.4 mg/ml. At testing concentrations, PBS, artificial 
saliva and formulation components do not interfere significantly 
with the UV absorption of 5-FU. The sensibility was less than 
0.0001 mg/ml. Intra- and inter-day variations, observed during col-
lection of experimental data, were lower than sensibility. 
 HPLC analyses were performed with a Shimadzu LC-10ADVP 
instrument equipped with a binary pump LC-10ADVP, an UV SPD-
M20A Diode Array detector, a 20 μl injector and a computer inte-
grating apparatus (EZ Start 7.3 software).  
2.2.9.1. Drug Content Into the Matrix 
 Aliquots of randomly selected matrix of each batch were accu-
rately weighed (25.0 ± 2.0 mg), transferred into a 25 ml flask, soni-
cated (Branson B 1200 cleaner, Branson Ultrasonic Corporation, 
Danbury, CT, USA), and brought to volume with acetonitrile to 
solubilize all components of formulation. The amount of 5-FU 
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loaded in the matrix was measured spectrophotometrically (max = 
263.3; E1%= 0.546 in acetonitrile). 
2.2.9.2. Drug Assay in Release Studies  
 5-FU released from tablets in buffer solution simulating saliva 
was evaluated spectrophotometrically at max 266 nm (E1%= 0.490 in 
simulating saliva). 
 5-FU release from tablets in the culture medium was assessed 
by HPLC analysis. Chromatographic separation was achieved on a 
reversed-phase C18-column (Gemini-NX, Phenomenex, 5 μm, 15 
cm x 4.6 mm), a mobile phase consisted of 100% 25 mM buffer 
phosphate (pH 6.8). The flow rate was set at 1 ml/min and the UV 
wavelength at 266 nm. In these conditions, the retention time for 5-
FU was 3.8 min. Standard curves were used for quantification of 
integrated areas under peaks. The calibration curves were per-
formed at the concentration range of 0.05 to 0.54 mg/ml. In these 
conditions LOQ was 0.0015 mg/ml and LOD was 0.0010 mg/ml. 
 The same analytical method was used to evaluate the cumula-
tive 5-FU recovery following drug release from tablets and permea-
tion throughout the outgrowths.  
2.2.10. Stability of Free 5-FU in Culture Medium 
 Due to stability and/or possible drug interaction with the com-
ponents of the culture medium, the active availability could be re-
duced. Concentration of 5-FU was observed after pre-incubation in 
culture medium for several days: no chemical alterations or de-
crease of concentration were observed in the drug after 10 days of 
pre-incubation.  
 
2.2.11. Data Analysis 
 All data, presented as average values of six experiments in du-
plicate, are reported with the standard deviations. Release data 
analyses were elaborated with Curve Expert version 1.3 and Kalei-
dagraph. Linear or non-linear least squares fitting methods were 
used to determine the optimum values for the parameters present in 
each equation. Fittings were validated by using chi-square test. 
Differences were statistically evaluated by the Student’s t-test; a p 
value of  0.05 was considered significant.  
3. RESULTS  
3.1. Effects of Different 5-FU Solutions on Cell Viability in SCC 
and HEK Cells: MTT Test 
 MTT assays were carried out to evaluate the cell viability upon 
treatment with five different 5-FU solution concentrations and to 
select the optimal conditions for the death of squamous carcinoma 
cells. HEK cells were used as a control cell line to verify eventual 
differences in the response to 5-FU. Fig. (1) shows that both the 
normal (HEK001) and neoplastic (SCC-4) cell lines were sensitive 
to 5-FU treatment only after 24 h. A pronounced increase in cell 
death was observed with the increase of drug concentration. Results 
were similar amongst the two cell lines. The 5-FU concentration 
that was exerting the optimal effect in terms of cell death was 1% 
(64.488 ± 5.2 in HEK001, 52.466 ± 6.3 in SCC-4), as expressed by 
a marked and significant reduction of overall viability. Above this 
concentration, cell death levels were too high [Fig. (1).] and the 
majority of the cells were detached from their plastic substratum. 
The 1% 5-FU solution was therefore deemed to be the best concen-

















Fig. (1). Effects of 5-FU solution on cell viability in HEK001 and SCC-4 cell lines: MTT test. Results after 5h and 24h of treatment with increasing concentra-
tions of 5-FU. Cell viability is expressed as the percentage of the OD value of 5-FU-treated cells compared with untreated controls. Histograms represent 
means ± SD (n = 6). 
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3.2. Effects of 5-FU Solution on Cell Viability in Oral Out-
growths: EM Observations 
 To verify the sensitivity of our newly developed 3D OSCC 
outgrowths to 5-FU, these were first grown until complete 3D dif-
ferentiation (this usually required 10 to 14 days) and then treated 
with 1% 5-FU solution for an additional 10 days. One of the advan-
tages of our outgrowth model is in fact the possibility to follow 
mid- to long-term exposures. As shown in Fig. (2), that shows a 
typical phase contrast micrograph obtained from an outgrowth that 
was differentiated for 10 days, after 10 additional days of treatment 
with 1% 5-FU solution, the outgrowth margins had considerably 
shrunk towards the initial biopsy fragment [Fig. (2). B] when com-
pared to the untreated control [Fig. (2). A] that instead covered the 
surface of the nylon membrane of the Transwell completely. These 
experiments were repeated with outgrowths obtained from 6 differ-
ent OSCC patients and the results obtained were consistent 
throughout, suggesting a definite effect of the 5-FU treatment on 
























Fig. (2). Morphological appearance of 3D outgrowths treated for 10 days 
with 1% 5-FU solution. 3D outgrowths were cultured for 10 days until com-
plete differentiation, and then treated for additional 10 days with (B) or 
without (A, untreated control) 1% (w/v) 5-FU solution. Arrows show the 
margins of the outgrowths as they recede towards the initial biopsy fragment 
as a consequence of the treatment. Bar = 1mm. 
3.3. 5-FU Release from Tablets 
 Drug release tests, in buffer solution simulating saliva, were 
performed using a flow through cell system able to simulate the 
buccal conditions, including the saliva turnover of the buccal envi-
ronment [32]. The cumulative amount of 5-FU released was plotted 
as a function of time as shown in Fig. (3). Each data point on the 
plot represents the mean of the recorded values. The drug discharge 
pattern showed a slow and regular drug release; it was elaborated 
according to equations usually applied in release studies [33]. The 
collected data showed that 5-FU release from tablets follows an 
Higuchian trend, thus suggesting that diffusion through the inert 




















Fig. (3). In vitro profile of 5-FU released from tablets containing 1% w/w of 
5-FU in buffer solution simulating saliva. Values are presented as means ± 
SD (n = 6). 
3.4. 5-FU Released from Tablets and Transferred Throughout 
3D Oral Outgrowths Into the Acceptor Medium  
 In order to evaluate levels of 5-FU released from tablets and 
transferred in the acceptor system across 3D outgrowths, at 48, 120 
and 192 h time points, the culture medium was withdrawn from the 
bottom plate (see sections 2.2.3.2 and 2.2.4) and analyzed by 
HPLC. Drug recovery was calculated both as the amount trans-
ferred into the bottom plate and the total amount released in the 
whole system. Results are summarized in the Table. 
Table. Amounts of 5-FU recovered in the bottom plate, in 
the whole system, and percentage of the dose re-
leased from tablets after administration of 1% 
(w/w) drug loaded tablets on 3D outgrowths grown 




ferred into the 
bottom plate 
(mg) ± SD 
5-FU recovered in 
the system (mg) ± 
SD 
Dose fraction (%) 
recovered in the 
system ± SD 
48 0.106 ± 0.003 0.191 ± 0.006 83.0 ± 2.5 
120 0.153 ± 0.007 0.204 ± 0.009 91.0 ± 1.7 
192 0.198 ± 0.008 0.225 ± 0.001 97.8 ± 0.4 
SD = Standard Deviation (n = 6) 
  
3.5. Effects of 5-FU Topically Delivered by Drug-loaded Tablets 
on Cell Viability in Oral Outgrowths: EM Observations 
 To evaluate the long-term effects of 5-FU on 3D oral out-
growths’ cell viability, these were treated for 48, 120 and 192 h 
with 1% 5-FU loaded tablets and prepared for transmission electron 
microscopy analysis. Fig. (4) shows that after 120 h of treatment, 
the squamous epithelial component of the cancerous oral out-
growths showed a marked reduction of its layers [Fig. (4). B] and 
some morphological features typical of apoptotic cell death [Fig. 
(4). D, E and F] when compared to the untreated controls [Fig. (4). 
A and C]. In particular, the treatment determined a complete loss of 
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the desmosomal junctions between the epithelial cells [Fig. (4). D] 
when compared to the untreated outgrowths [Fig. (4). C], chromatin 
and cytoplasm condensation [Fig. (4). E] and presence of apoptotic 
bodies [Fig. (4). F]. After 192 h of treatment with the 1% 5-FU 
loaded tablets all cells were detached and therefore it was not pos-
sible to perform any kind of morphological evaluation. These ex-
periments were repeated with outgrowths obtained from 6 different 
OSCC patients and the results obtained were very consistent, sug-
gesting that 5-FU treatment determined induction of apoptosis.  
3.6. Effects of 5-FU Topically Delivered by Drug-loaded Tablets 
on Cell Viability in Oral Outgrowths: TUNEL Staining 
 In order to confirm that long-term 5-FU treatment did indeed 
induce apoptotic cell death in our 3D OSCC model, as already sug-
gested by the EM observations, TUNEL was employed. As shown 
in Fig. (5), after 120 h of treatment with 1% 5-FU loaded tablets, 
the vast majority of nuclei were stained positively for TUNEL [Fig. 
(5). B] compared to the untreated control [Fig. (5). A] where only a 
few nuclei were positive. The graph in Fig. (5). C shows that at 48 
h TUNEL positive cells were few (around 10%) in both treated 
outgrowths and untreated controls; after 120 h there was a signifi-
cant increase of TUNEL positive cells in treated outgrowths when 
compared to untreated controls (80.43 ± 10.87 vs 12.54 ± 5.6, 
p<0.001); finally, after 192 h the nuclei of the few cells that were 
still attached to their substrate in the treated outgrowths were all 
positive for the TUNEL assay whereas the untreated controls were 
still showing, even after such a long time in culture, very low levels 
of apoptosis. 
4. DISCUSSION 
 The current treatment of OSCC is not still satisfactory in terms 
of patient survival and the role of chemotherapy in the treatment of 
patients with oral cancer is not well established yet. Consequently, 
there is an urgent need for new treatment paradigms to achieve 
better efcacy, and avoid the side effects and long term morbidity 
of existing therapeutic protocols. The ideal situation would be to 
nd drug formulations that will allow lower individual doses but 





















Fig. (4). Morphological appearance of 3D outgrowths treated with 1% 5-FU tablets for 120 hours. 3D outgrowths were grown until complete 3D differentia-
tion (10-14 days), and then treated with 1% (w/w) 5-FU tablets for 120 h (B, D, E and F). A and C are untreated controls (drug unloaded matrix tablets). In B it 
is possible to observe a marked reduction of the epithelial layers. In D loss of desmosomal junctions between the epithelial cells is shown. Arrows in C show 
desmosomes. E and F show typical features of apoptosis such as chromatic condensation and apoptotic bodies respectively. Bars in A, B, E and F = 5μm, bars 
in C and D = 500nm. 
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this objective, the chemotherapeutic agent 5-FU, loaded into matrix 
tablets, locally applied on mucosal neoplastic lesions could increase 
the drug levels in the tumor area, and allow treating OSCC by de-
livering small drug amounts, just sufficient to give the desired ef-
fect on the neoplastic lesion without the severe systemic adverse 
effects. Cytotoxic chemotherapy is routinely used in the treatment 
of cancer, and has been an important factor in increasing 5-year 
survival rates for some types of cancer. 
 In this study, the effect of locally applied 5-FU on cell death 
was evaluated both on classic cell line models (HEK001 and SCC-
4) and on a three-dimensional OSCC outgrowth model. 
 Initially, the optimal drug dose was established by delivery of 
solutions containing different amounts of 5-FU. The solution con-
taining 1% of 5-FU resulted effective in inducing cell death with 
complete eradication of cell colonies. In a previous paper [31] we 
observed that solution containing 1% of 5-FU induced high degrees 
of apoptosis and foci of necrosis also on both a multilayer culture of 
the human TR146 keratinocyte cell line and healthy porcine buccal 
mucosa.  
 The drug solution was then tested on 3D OSCC outgrowths 
where it determined a reduction of outgrowth proliferation as 
shown by the marked shrinking of the margins of the outgrowth 
during the treatment.  
 The observed reduction in cell viability prompted us to investi-
gate the effects of local application of solid dosage forms on the 3D 
OSCC outgrowth model. 
 Drug loaded matrices containing 1% of 5-FU were designed 
using the acrylic/methacrylic acid copolymer (described in USP/NF 
as ammonio methacrylate copolymer “type B”) as this is a biocom-
patible, non-swelling and insoluble copolymer, sparingly permeable 
to water, unaffected by physiological pH values, that has been 
widely used in the preparation of various drug delivery systems. 
Buccal tablets were then prepared by direct compression of drug 
loaded matrices. A precondition for locoregional delivery of drugs 
is, in addition to the biocompatibility of the putative formulation, an 
appropriate drug release at the target site. To verify the ability of 
tablets to discharge drug amounts adequate to produce effective 
concentrations on tumoral tissue, the cumulative release of 5-FU 
into the saliva was determined in a time-dependent manner. To act 
as a reservoir, which provides a drug depot adjacent to the cancer 
lesion, a rapid release is not desired. Our results showed a slow and 
regular drug release that follows an Higuchian trend, thus suggest-
ing that diffusion through the inert polymer matrix is the prevailing 
mechanism of dissolution. 
 The release of 5-FU from tablets and the drug transfer in the 
bottom well of the Transwell system across outgrowths, was evalu-
ated at 48, 120 and 192 h time points. From the data reported in the 
Table it is possible to observe that after 48 h, about 83% of the 5-
FU was discharged from tablets, whereas about 91 % was released 
after 120 h. Of course, after 192 h, the drug dose released was near 
the loaded (98%). 
 After showing that the drug was released from the tablets into 
culture medium, its activity was determined in 3D OSCC out-
growths by analysing cell death induction both morphologically by 
transmission electron microscopy and enzymatically by TUNEL 
assay. Our results show that after 120 h of treatment, when, as al-
















Fig. (5). Effects of 1% 5-FU loaded tablets on apoptosis in 3D oral outgrowths: TUNEL staining. 3D outgrowths were grown until complete 3D differentiation 
(10-14 days), and then treated with 1% (w/w) 5-FU tablets for 48, 120 and 192 h, and prepared for TUNEL assay. A and B are typical light microscope fields 
(400x magnification) obtained from outgrowths treated with drug loaded (B) or unloaded (untreated control, A) tablets for 120 h . Bar = 40 μm. C is the graph 
representing the means ± SD of quantifications obtained from 6 different experiments in duplicate after 48, 120 and 192 h in untreated controls (UC) and 
treated outgrowths (1% 5-FU). 
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tablets through the Matrigel and into the cell layers, 5-FU caused 
loss of cell-cell communications and apoptotic cell death. This ini-
tially caused a dramatic reduction in the number of epithelial cell 
layers and eventually, after 192 h, when almost all the drug had 
been released from the tablet, determined a complete disaggregation 
of the 3D OSCC outgrowths and the death of all the cells contained 
within by apoptosis. 
 Since, beyond the drug used, other formulation components 
could cause some consequence on cell viability, analogous analyses 
were performed after application of drug unloaded matrix tablets. 
No significant effects were observed and no signs of cell death was 
found. The acrylic/methacrylic acid copolymer should not consti-
tute a key obstacle to local drug delivery on tumor lesions. 
5. CONCLUSIONS 
 Here we report for the first time the use of a newly developed 
3D OSCC outgrowth as an ex vivo model to test the effects of drugs 
administration on neoplastic human oral mucosa.  
 Matrix tablet formulations containing 1% of 5-FU appear to be 
suitable for the release of adequate drug amounts and could be con-
sidered as a promising new approach to locoregional treatment of 
OSCC. The results herein reported represent a valuable basis for 
detailed animal studies addressed to the in vivo application.  
 We believe that by locoregional drug delivery the risks of toxic-
ity associated with the anticancer chemoterapy must be very low as 
a consequence of a summary of different factors, such as the avoid-
ance of systemic delivery, the very low drug doses administered, 
the high drug concentration next to the target tissue and the che-
motherapic agent chosen. Moreover, locoregional OSCC therapy 
could improve patient compliance. 
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